Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Enzymatica

2.27 SEK-5.42 %19/11 15:50
Less than 1K followers

ENZY

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-5.42 %
+19.47 %
+15.52 %
-8.47 %
+19.47 %
+20.11 %
-25.72 %
-75.49 %
-60.26 %

Enzymatica is a life science company that develops and sells medical devices against infectious diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray, which can prevent colds and shorten the duration of the illness. The product has been launched in several markets and the strategy is to expand to more markets through partners. The head office is located in Lund.

Read more
Market cap
551.01M SEK
Turnover
190.41K SEK
Revenue
53.9M
EBIT %
-95.3 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18/2
2027

Annual report '26

28/4
2027

Interim report Q1'27

13/5
2027

General meeting '27

Regulatory press release2026-10-29 08:30

Kvartalsrapport Q3/2026 ColdZyme tar steget in på nya marknader

Enzymatica
Regulatory press release2026-10-29 08:30

Quarterly report Q3/2026 ColdZyme enters new markets

Enzymatica
Press release2026-10-28 10:00

Truls Möregårdh investerar i Enzymatica och blir ambassadör för ColdZyme

Enzymatica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-10-28 10:00

Truls Möregårdh invests in Enzymatica and becomes ColdZyme ambassador

Enzymatica
Regulatory press release2026-10-27 13:05

Guðmundur Pálmason lämnar Enzymaticas styrelse

Enzymatica
Regulatory press release2026-10-27 13:05

Guðmundur Pálmason steps down from Enzymatica’s Board of Directors

Enzymatica
Press release2026-10-27 09:00

Enzymatica rekryterar Katja Margell som Director of Investor Relations & Corporate Affairs

Enzymatica
Press release2026-10-27 09:00

Enzymatica appoints Katja Margell as Director of Investor Relations & Corporate Affairs

Enzymatica
Regulatory press release2026-10-22 13:50

Kommuniké från extra bolagsstämma i Enzymatica AB (publ) den 22 oktober 2026

Enzymatica
Regulatory press release2026-10-22 13:50

Bulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 October 2026

Enzymatica
Regulatory press release2026-10-21 13:30

Enzymatica tar steget in i MENA – tecknar distributionsavtal för ColdZyme® i Jordanien och Irak

Enzymatica
Regulatory press release2026-10-21 13:30

Enzymatica enters MENA – signs distribution agreement for ColdZyme® in Jordan and Iraq

Enzymatica
Press release2026-10-16 11:10

STADA lanserar Virustad i Tyskland – baserad på Enzymaticas ColdZyme®-teknologi

Enzymatica
Press release2026-10-16 11:10

STADA launches Virustad in Germany – based on Enzymatica's ColdZyme® technology

Enzymatica
Regulatory press release2026-09-28 18:02

Kallelse till extra bolagsstämma i Enzymatica AB (publ)

Enzymatica
Regulatory press release2026-09-28 18:02

Notice of Extraordinary General Meeting in Enzymatica AB (publ)

Enzymatica
Press release2026-08-27 13:45

Enzymatica stärker ledningsgruppen med kommersiell och vetenskaplig kompetens

Enzymatica
Press release2026-08-27 13:45

Enzymatica strengthens its management team with commercial and scientific expertise

Enzymatica
Regulatory press release2026-07-16 08:30

Kvartalsrapport Q2/2026 Fortsatt fokus på internationell expansion och en stärkt organisation

Enzymatica
Regulatory press release2026-07-16 08:30

Quarterly report Q2/2026 Continued focus on international expansion and a stronger organization

Enzymatica